Tag Archives: NASDAQ:RVNC

Guggenheim Remains a Buy on Revance Therapeutics

In a report released yesterday, Rohit Vanjani from Guggenheim reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $44. The company’s shares closed yesterday at $35.90, close to its 52-week high of $37.45. According to

Piper Jaffray Believes Revance Therapeutics (NASDAQ: RVNC) Won’t Stop Here

In a report issued on December 5, David Amsellem from Piper Jaffray reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $51. The company’s shares closed yesterday at $33.65, close to its 52-week high of

Revance Therapeutics Received its Third Buy in a Row

After Cantor Fitzgerald and Piper Jaffray assigned a Buy rating to Revance Therapeutics in the last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang initiated coverage with a Buy rating on Revance Therapeutics (NASDAQ:

Revance Therapeutics Gets a Buy Rating from Piper Jaffray

In a report issued on October 24, David Amsellem from Piper Jaffray reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC), with a price target of $28. The company’s shares closed yesterday at $25.40. According to TipRanks.com, Amsellem is a

Cantor Fitzgerald Keeps a Buy Rating on Revance Therapeutics

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $25.50. Chen noted: “RT002 injectable has the potential to be a longer

Revance Therapeutics Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $25.05. Chen noted: “We hosted our annual Cantor Fitzgerald Healthcare Conference in